What is the risk of hepatitis B infection or reactivation in a patient receiving chemotherapy for multiple myeloma, and what screening and prophylaxis are recommended?

Risk of Hepatitis B Reactivation in Multiple Myeloma Patients Receiving Chemotherapy

All patients with multiple myeloma must be screened for hepatitis B before starting chemotherapy, and those who are HBsAg-positive or have resolved HBV infection (anti-HBc-positive) require antiviral prophylaxis due to the substantial risk of reactivation, particularly with autologous stem cell transplantation.

Screening Requirements

Screen all multiple myeloma patients for HBsAg and anti-HBc antibodies before initiating any chemotherapy. 1, 2 This is non-negotiable regardless of risk factors or clinical presentation.

For patients who are HBsAg-negative but anti-HBc-positive (resolved infection):

• Measure baseline HBV DNA levels before starting therapy 2
• Consider anti-HBs testing to further stratify risk, though this may be less protective under immunosuppressive conditions 2, 3

Risk Stratification

HBsAg-Positive Patients (Chronic HBV)

The risk of reactivation ranges from 15-50% during chemotherapy and can exceed 75% with stem cell transplantation. 2 Without prophylaxis and timely management, this can progress to fulminant hepatitis and death. 4

Resolved HBV Infection (HBsAg-negative, anti-HBc-positive)

• Overall reactivation risk: 5-9% in multiple myeloma patients 5, 3
• Cumulative incidence at 2 years: 5-8% 5, 3
• Cumulative incidence at 5 years: 8-14% 5, 3
• Risk increases significantly with autologous stem cell transplantation (ASCT): 6.5% reactivation rate 6
• Anti-HBs-negative status increases risk approximately 4-fold (HR 4.64) 3

Critical distinction for multiple myeloma: Unlike lymphoma patients, approximately 20% of MM patients develop HBV reactivation after 2 years from therapy initiation, requiring extended monitoring. 4 This is due to prolonged treatment durations with novel agents.

Prophylaxis Recommendations

HBsAg-Positive Patients

Initiate antiviral prophylaxis before starting any systemic chemotherapy. 1, 2

• Preferred agents: Entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) 1, 2
• Duration: Continue throughout chemotherapy AND for at least 12 months after the last dose of anticancer therapy 1
• For high-risk scenarios (including ASCT): Extend prophylaxis to at least 18 months after completing therapy 2
• Obtain baseline HBV DNA and monitor every 6 months during antiviral therapy 1

Resolved HBV Infection (Anti-HBc-positive, HBsAg-negative)

For patients receiving ASCT or B-cell depleting therapies: Start antiviral prophylaxis before therapy and continue for at least 12-18 months after completion. 1, 2 The risk is classified as high (>10%) in this population. 2

For patients NOT receiving ASCT or B-cell depleting agents: Two acceptable approaches exist:

1. Prophylaxis approach (preferred for anti-HBs-negative patients): Start entecavir, TDF, or TAF before chemotherapy and continue for 12 months after completion 2, 3

2. Preemptive monitoring approach: Monitor HBV DNA every 4 weeks during therapy, with treatment initiation if HBV DNA becomes detectable or ALT rises >2x upper limit of normal 1, 5 This requires strict adherence to monitoring schedules.

Given the unique pattern of late reactivation in multiple myeloma (up to 2+ years), the prophylaxis approach is safer than monitoring alone for most patients. 4, 5

Monitoring Protocol

During Prophylaxis

• HBV DNA every 6 months 1
• Liver function tests (ALT, AST) at regular intervals

If Using Preemptive Strategy

• HBV DNA every 4 weeks during active chemotherapy 1
• Increase to every 2 weeks if HBV DNA becomes detectable 1
• Continue monitoring for at least 2 years after completing therapy due to late reactivation risk in MM 4, 5

Common Pitfalls

Do not stop antiviral prophylaxis at 6 months. The standard 6-month duration is insufficient for multiple myeloma patients, particularly those receiving ASCT or prolonged novel agent therapy. 1, 2, 7

Do not assume anti-HBs positivity provides complete protection. While higher anti-HBs levels (>100 IU/L) may offer some protection, immunosuppressive therapy can reduce this effectiveness. 2, 3

Do not use lamivudine as first-line prophylaxis. Despite being studied in older trials, entecavir and tenofovir agents have higher potency and superior resistance profiles. 1, 2

Do not neglect screening in low-prevalence areas. Even in regions with lower HBV prevalence, the consequences of missed reactivation are severe, and screening is cost-effective. 1

Impact on Outcomes

HBsAg-positive MM patients have significantly worse overall survival and progression-free survival compared to HBsAg-negative patients (p<0.01), emphasizing the importance of proper HBV management. 7 However, with appropriate prophylaxis and monitoring, HBV reactivation is reversible and does not adversely affect survival when managed promptly. 6

Antiviral treatment in HBV-infected MM patients significantly improves overall survival (p=0.016), particularly when the monoclonal gammopathy may be HBV-driven. 8